Medarex Pipeline Hearty As Investors Focus On Dicey Melanoma Bid
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase III results with ipilimumab in skin cancer due by the end of this year; income from just-approved Simponi likely to pump value meanwhile.